One patent covers the processes to prepare the clinical product for injection and is a divisional patent application (JP 2018-164332) of an earlier approved patent (JP 6617104). The now approved divisional patent is considered very important for Isofol because it, more explicitly, provides protection for preparing the Lyophilisate (freeze dried) Clinical Product, from the API (arfolitixorin hemisulfate). This patent is valid until 2034.
The other newly granted patent is a use patent (JP 6734308) with dose regimens including "multiple bolus injections" of arfolitixorin as an important feature in combination with both bolus injection and infusion of the anti-cancer agent 5-FU. This patent covers the ongoing AGENT study regimen with respect to dose levels and timings. This patent is valid until 2038.
Ulf Jungnelius, CEO of Isofol, commented: "It is most gratifying that we now have strengthened our patent rights in the Japanese market as well. Combined with our recently concluded license agreement with
For further information, please contact
Jarl Ulf Jungnelius, M.D., Chief Executive Officer
E-mail: jungnelius@isofolmedical.com
Phone: +46 (0) 709 16 89 55
Certified Adviser
E-mail: info@fnca.se
Phone: +46 (0) 8 528 003 99
The information was submitted for publication, through the agency of the contact person set out above, at
About arfolitixorin
Arfolitixorin is Isofol's proprietary drug candidate being developed to increase the efficacy of standard of care chemotherapy for advanced colorectal cancer. The drug candidate is currently being studied in a global Phase 3 study, AGENT. As the key active metabolite of the widely used folate-based drugs, arfolitixorin can potentially benefit all patients with advanced colorectal cancer, as it does not require complicated metabolic activation to become effective.
About
www.isofolmedical.com
https://news.cision.com/isofol-medical-ab--publ-/r/strengthened-patent-protection-for-arfolitixorin-in-japan,c3186416
https://mb.cision.com/Main/15598/3186416/1300565.pdf
(c) 2020 Cision. All rights reserved., source